A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Soiffer, RJ; Kim, HT; McGuirk, J; Horwitz, ME; Johnston, L; Patnaik, MM; Rybka, W; Artz, A; Porter, DL; Shea, TC; Boyer, MW; Maziarz, RT; Jagasia, MH; Shaughnessy, PJ; Gergis, U; Safah, H; Reshef, R; DiPersio, JF; Stiff, PJ; Vusirikala, M; Szer, J; Holter, J; Levine, JD; Martin, PJ; Pidala, JA; Lewis, ID; Ho, VT; Alyea, EP; Ritz, J; Glavin, F; Westervelt, P; Chen, Y-B

Published Date

  • December 2, 2016

Published In

Volume / Issue

  • 128 / 22

Published By

Pages

  • 7

Electronic International Standard Serial Number (EISSN)

  • 1528-0020

International Standard Serial Number (ISSN)

  • 0006-4971

Conference Name

  • 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Conference Location

  • San Diego, CA

Conference Start Date

  • December 3, 2016

Conference End Date

  • December 6, 2016